Integra LifeSciences (NASDAQ:IART) Shares Up 6.2% on Analyst Upgrade

Integra LifeSciences Holdings Corporation (NASDAQ:IART) was up 6.2% during mid-day trading on Thursday after Truist Financial raised their price target on the stock from $14.00 to $19.00. Truist Financial currently has a hold rating on the stock. Integra LifeSciences traded as high as $20.00 and last traded at $19.9350. Approximately 97,377 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 888,973 shares. The stock had previously closed at $18.78.

A number of other brokerages also recently commented on IART. BMO Capital Markets assumed coverage on Integra LifeSciences in a research note on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price objective for the company. Citigroup reiterated a “neutral” rating and issued a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday, July 8th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a report on Thursday, June 18th. Wells Fargo & Company upped their price target on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen raised shares of Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $18.33.

Institutional Investors Weigh In On Integra LifeSciences

Institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in Integra LifeSciences in the fourth quarter worth approximately $4,722,000. Hsbc Holdings PLC acquired a new position in shares of Integra LifeSciences during the 4th quarter valued at $879,000. Tejara Capital Ltd raised its stake in shares of Integra LifeSciences by 42.6% in the 4th quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock worth $2,134,000 after buying an additional 51,300 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Integra LifeSciences by 15.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 526,302 shares of the life sciences company’s stock worth $6,537,000 after buying an additional 71,950 shares in the last quarter. Finally, Systematic Financial Management LP lifted its holdings in shares of Integra LifeSciences by 4.5% in the fourth quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock valued at $13,769,000 after buying an additional 48,094 shares during the period. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

The company has a fifty day moving average price of $16.68 and a two-hundred day moving average price of $12.98. The firm has a market cap of $1.56 billion, a price-to-earnings ratio of -3.10, a price-to-earnings-growth ratio of 1.27 and a beta of 1.22. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The firm had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. During the same period in the previous year, the company earned $0.41 earnings per share. Integra LifeSciences’s revenue was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, equities research analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.